Gansu Longshenrongfa Pharmaceutical (300534.SZ) Obtains Medical Device Registration Certificate for Hemodialysis Concentrate
Stock News
Nov 28
Gansu Longshenrongfa Pharmaceutical (300534.SZ) announced that on November 28, 2025, the company received the Medical Device Registration Certificate issued by the National Medical Products Administration for its hemodialysis concentrate.
The hemodialysis concentrate consists of two parts: Concentrate A and Concentrate B. Concentrate A is composed of sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2·2H2O), magnesium chloride (MgCl2·6H2O), glacial acetic acid (CH3COOH), and dialysis water. Concentrate B contains sodium bicarbonate (NaHCO3) and dialysis water.
The product is indicated for hemodialysis treatment of acute renal failure and chronic renal failure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.